Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ | --- | --- | --- | --- | |------------------------------------------------------------|-------------------------------------------- ...

AmerisourceBergen Corporation (ABC) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Bennett Murphy - SVP, IR Steven Collis - Chairman, President & CEO James Cleary - EVP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co. Michael Cherny - Bank of America Merrill Lynch George Hill - Deutsche Bank Charles Rhyee - Cowen and Company Eric Percher - Nephron Research Eric Coldwell - Baird Kevin Caliendo - UBS Steven Valiquette - Barclays Bank A.J. Rice - Credit Sui ...

Financial Performance - Q4 FY2022 - Revenue remained consistent year-over-year at $61.2 billion, reflecting a 3.8% increase[6] - Gross profit decreased by 4.1% to $2.0 billion on a GAAP basis, but increased by 4.8% to $2.1 billion on an adjusted (non-GAAP) basis[6] - Operating income decreased by 19.1% to $455 million (GAAP) but increased by 6.8% to $741 million (Adjusted)[6] - Net income attributable to AmerisourceBergen decreased by 32.7% to $295 million (GAAP) but increased by 8.4% to $546 million (Adjusted)[6] - Diluted earnings per share decreased by 32.7% to $1.40 (GAAP) but increased by 8.8% to $2.60 (Adjusted)[6] Financial Performance - FY2022 - Revenue increased by 11.5% year-over-year to $238.6 billion[7] - Gross profit increased by 19.5% to $8.3 billion (GAAP) and 27.9% to $8.4 billion (Adjusted)[7] - Operating income increased by 0.5% to $2.4 billion (GAAP) and 19.5% to $3.2 billion (Adjusted)[7] - Net income attributable to AmerisourceBergen increased by 10.3% to $1.7 billion (GAAP) and 20.7% to $2.3 billion (Adjusted)[7] - Diluted earnings per share increased by 8.8% to $8.04 (GAAP) and 19.1% to $11.03 (Adjusted)[7] FY2023 Guidance (Consolidated) - Revenue is projected to increase by 5% to 7% as reported, or 6% to 8% on a constant currency basis[14] - Adjusted operating income is expected to increase by 0% to 3% as reported, or 3% to 6% on a constant currency basis, and 3% to 5% excluding COVID-19 contributions, or 6% to 8% on a constant currency basis excluding COVID-19[14] - Adjusted diluted earnings per share are projected to be between $11.30 and $11.60, representing growth of 2% to 5% as reported, or 4% to 7% on a constant currency basis, and 7% to 9% excluding COVID-19 contributions, or 9% to 11% on a constant currency basis excluding COVID-19[14] - Adjusted free cash flow is estimated to be approximately $2 billion[14]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 2 ...

AmerisourceBergen Corporation (ABC) Q2 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President-Investor Relations Steve Collis - Chairman, President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Lisa Gill - JPMorgan Charles Rhyee - Cowen Steven Valiquette - Barclays Eric Percher - Nephron Research Eric Coldwell - Baird George Hill - Deutsche Bank Mic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware ...

| --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | Q1 FY2022 Financial Results February 2, 2022 | | | | | | | | | | | | | | | | | | | | | | | Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of ...

Financial Data and Key Metrics Changes - AmerisourceBergen reported a revenue growth of 13% year-over-year, reaching $59 billion for Q1 2022 [8] - Adjusted operating income increased by 21%, while adjusted EPS grew by 18% [8][32] - Consolidated revenue grew about 14% to $59.6 billion, with consolidated gross profit increasing by 41% to $2 billion [32][33] - The effective income tax rate was 21.3%, consistent with prior year [35] - Adjusted free cash flow was $809 million, with a cash balance of $3.2 billion at the end of the quarter [36] Business Line Data and Key Metrics Changes - U.S. Healthcare Solutions segment revenue increased by 2.7% to $53 billion, driven by sales growth in specialty physician services and MWI Animal Health [37] - International Healthcare Solutions segment revenue was $6.6 billion, with $5.6 billion attributed to the Alliance Healthcare acquisition [42] - Segment operating income for U.S. Healthcare Solutions was $569 million, representing a growth of 0.6% [38] - International Healthcare Solutions segment operating income was $180 million, up 253% on a reported basis [43] Market Data and Key Metrics Changes - Alliance Healthcare's performance has been strong, contributing significantly to the COVID-19 response in multiple countries [44] - The company is seeing significant growth in Alphega's membership as independent pharmacies recognize the value of working with Alliance [19] Company Strategy and Development Direction - The company focuses on pharmaceutical-centric strategies, strong customer relationships, and leadership in specialty pharmaceuticals [9][31] - AmerisourceBergen aims to expand its leadership in specialty and enhance its role in pharmaceutical innovation and access globally [20][52] - The company is committed to ESG initiatives and has published its sixth Annual Global Sustainability Report [26][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the complexities of the healthcare landscape and highlighted the importance of partnerships in addressing COVID-19 [11][29] - The company raised its fiscal 2022 U.S. Healthcare Solutions segment operating income guidance to a range of $2.375 billion to $2.45 billion, reflecting positive trends in COVID therapies [41] Other Important Information - The company renewed its supply agreement with Express Scripts through 2026, emphasizing long-term partnerships [10] - AmerisourceBergen's role in distributing COVID-19 therapies has been pivotal, with over 100 million vaccines distributed worldwide [60] Q&A Session Summary Question: Impact of wage inflation in Europe - Management acknowledged higher labor and transportation costs but noted that these were included in guidance and that the company is managing through inflation effectively [55][56] Question: Role in new COVID antivirals - Management highlighted their significant role in distributing COVID therapies and emphasized their adaptability and strong relationships with government entities [60][61] Question: Specialty and biosimilars growth - Management indicated that specialty physician services are performing well, with increasing acceptance of biosimilars contributing positively to the business [66][70] Question: Drug pricing environment - Management stated that brand drug inflation is in line with expectations and that generic deflation rates remain stable [78] Question: Express Scripts renewal details - Management confirmed no significant changes to pricing or economics in the Express Scripts renewal, emphasizing the importance of long-term partnerships [81][84]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delawa ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | J.P. Morgan | | | | | | | Healthcare | | | | | | | Conference JANUARY 2022 | | | | | | | Steve Collis Chairman, President & CEO | | | | | | Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securitie ...